[
  {
    "ts": "2025-11-11T00:00:00+00:00",
    "headline": "Eli Lilly cuts surprising deals with upstart biotech players",
    "summary": "Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated deal with the White House. The move underlines Eli Lilly’s ambition to expand beyond its dominant ...",
    "url": "https://www.thestreet.com/investing/stocks/eli-lilly-cuts-surprising-deals-with-upstart-biotech-players",
    "source": "TheStreet",
    "provider": "yfinance",
    "raw": {
      "id": "3af520e7-cb4a-3151-a9fd-c264d4c52b6f",
      "content": {
        "id": "3af520e7-cb4a-3151-a9fd-c264d4c52b6f",
        "contentType": "STORY",
        "title": "Eli Lilly cuts surprising deals with upstart biotech players",
        "description": "",
        "summary": "Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated deal with the White House. The move underlines Eli Lilly’s ambition to expand beyond its dominant ...",
        "pubDate": "2025-11-11T00:00:00Z",
        "displayTime": "2025-11-11T00:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/thestreet_881/57caa2ddd6451258ff2dbf63f7196090",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Z0L6ukO6JGXpAK26OgNTjA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet_881/57caa2ddd6451258ff2dbf63f7196090.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d3v49gU8yXup7hM9Rr7aaQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/thestreet_881/57caa2ddd6451258ff2dbf63f7196090.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TheStreet",
          "url": "https://www.thestreet.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thestreet.com/investing/stocks/eli-lilly-cuts-surprising-deals-with-upstart-biotech-players",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-cuts-surprising-deals-000000281.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T09:25:00+00:00",
    "headline": "Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?",
    "summary": "Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.",
    "url": "https://www.fool.com/investing/2025/11/11/win-intense-battle-rule-glp-1-drug-lly-nvo-pfe/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "7600dc29-a7f0-397a-8c3c-7b2508f19c52",
      "content": {
        "id": "7600dc29-a7f0-397a-8c3c-7b2508f19c52",
        "contentType": "STORY",
        "title": "Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?",
        "description": "",
        "summary": "Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.",
        "pubDate": "2025-11-11T09:25:00Z",
        "displayTime": "2025-11-11T09:25:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/0f189b86e73e67f4cf765d58dbf57476",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A package of a weight-loss drug next to a barbell.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uy.JmKH8mGx7AIwWfdl7XA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/0f189b86e73e67f4cf765d58dbf57476.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A1zrw5Cb3qAMPzn97Rm55w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/0f189b86e73e67f4cf765d58dbf57476.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/11/win-intense-battle-rule-glp-1-drug-lly-nvo-pfe/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/whos-winning-intense-battle-rule-092500402.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T10:30:00+00:00",
    "headline": "Obesity Drugs Are About to Go Mass-Market",
    "summary": "For most of Big Pharma, drug discounts have largely been about damage control.  After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief.  For  Eli Lilly’s    David Ricks  and  Novo Nordisk’s    Mike Doustdar,  who paid their own visit to the White House last week, the calculus is different.",
    "url": "https://www.wsj.com/health/pharma/ozempic-glp1-weight-loss-mass-market-f70f8484?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "b2aa9d81-f8af-30ce-a574-a07b350656b9",
      "content": {
        "id": "b2aa9d81-f8af-30ce-a574-a07b350656b9",
        "contentType": "STORY",
        "title": "Obesity Drugs Are About to Go Mass-Market",
        "description": "",
        "summary": "For most of Big Pharma, drug discounts have largely been about damage control.  After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief.  For  Eli Lilly’s    David Ricks  and  Novo Nordisk’s    Mike Doustdar,  who paid their own visit to the White House last week, the calculus is different.",
        "pubDate": "2025-11-11T10:30:00Z",
        "displayTime": "2025-11-11T10:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/b2aa9d81-f8af-30ce-a574-a07b350656b9/obesity-drugs-are-about-to-go.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/d9fbb83aa02eec1c9b51828685ea6e31",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r3EYtfWi7DUenDdrNOIVjQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/d9fbb83aa02eec1c9b51828685ea6e31.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/T5qoowdQPCQB7Wmdu4lvWA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/d9fbb83aa02eec1c9b51828685ea6e31.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/ozempic-glp1-weight-loss-mass-market-f70f8484?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T04:37:55+00:00",
    "headline": "2 Volatile Stocks with Impressive Fundamentals and 1 Facing Headwinds",
    "summary": "Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.",
    "url": "https://finance.yahoo.com/news/2-volatile-stocks-impressive-fundamentals-043755591.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "7514dfe8-b5a9-34f9-be81-a13ba33c55c9",
      "content": {
        "id": "7514dfe8-b5a9-34f9-be81-a13ba33c55c9",
        "contentType": "STORY",
        "title": "2 Volatile Stocks with Impressive Fundamentals and 1 Facing Headwinds",
        "description": "",
        "summary": "Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.",
        "pubDate": "2025-11-11T04:37:55Z",
        "displayTime": "2025-11-11T04:37:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/0853feacc1714816055c5fd627257ffb",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "COIN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JPzvkxTm6sZVUu6VjgxGQw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/0853feacc1714816055c5fd627257ffb.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d2yqxW.HvCKxREHWmQROmg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/0853feacc1714816055c5fd627257ffb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-volatile-stocks-impressive-fundamentals-043755591.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-volatile-stocks-impressive-fundamentals-043755591.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ELAN"
            },
            {
              "symbol": "COIN"
            },
            {
              "symbol": "DXCM"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T13:52:00+00:00",
    "headline": "Trifecta Health and Trifecta Med Spa Announce Strategic Cooperation to Enhance Patient Access to Weight Loss Treatments",
    "summary": "Trifecta Health and Trifecta Med Spa are excited to announce two strategic cooperations aimed at improving patient access to high-quality obesity treatments. These cooperations will streamline the process for patients to receive FDA-approved medications directly from the manufacturers at the most affordable prices.",
    "url": "https://finance.yahoo.com/news/trifecta-health-trifecta-med-spa-135200758.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "320a1c91-124f-3ac6-a378-c3b4408366ed",
      "content": {
        "id": "320a1c91-124f-3ac6-a378-c3b4408366ed",
        "contentType": "STORY",
        "title": "Trifecta Health and Trifecta Med Spa Announce Strategic Cooperation to Enhance Patient Access to Weight Loss Treatments",
        "description": "",
        "summary": "Trifecta Health and Trifecta Med Spa are excited to announce two strategic cooperations aimed at improving patient access to high-quality obesity treatments. These cooperations will streamline the process for patients to receive FDA-approved medications directly from the manufacturers at the most affordable prices.",
        "pubDate": "2025-11-11T13:52:00Z",
        "displayTime": "2025-11-11T13:52:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/0ef6da2f95469a4c5c9661c95ec8fb2d",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bm294OC8_9xU88T7zaRClQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/0ef6da2f95469a4c5c9661c95ec8fb2d.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Rwhy1yA9h0wgXbURMQ.zkg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/0ef6da2f95469a4c5c9661c95ec8fb2d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/trifecta-health-trifecta-med-spa-135200758.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/trifecta-health-trifecta-med-spa-135200758.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T16:31:52+00:00",
    "headline": "Eli Lilly stock soars to new highs, Novo Nordisk lags. Here's why.",
    "summary": "Eli Lilly (LLY) stock is trading at record highs after the pharmaceutical company reached a deal with the White House to offer weight-loss drugs at a discount. Novo Nordisk (NVO), which was also part of Trump's GLP-1 deal, has not seen its stock climb to fresh record highs on the agreement. BMO Capital Markets' managing director of BioPharma equity research, Evan Seigerman, joins Market Catalysts with Julie Hyman to discuss the difference in stock reactions from the pharma giants. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finance.yahoo.com/video/eli-lilly-stock-soars-highs-163152645.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "6532f328-fa04-3da0-bf29-d34662a76319",
      "content": {
        "id": "6532f328-fa04-3da0-bf29-d34662a76319",
        "contentType": "VIDEO",
        "title": "Eli Lilly stock soars to new highs, Novo Nordisk lags. Here's why.",
        "description": "<p>Eli Lilly (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/LLY\">LLY</a>) stock is trading at record highs after the pharmaceutical company reached a <a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/video/trump-inks-eli-lilly-novo-223000229.html\">deal with the White House</a> to offer weight-loss drugs at a discount. Novo Nordisk (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>), which was also part of Trump's GLP-1 deal, has not seen its stock climb to fresh record highs on the agreement.</p>\n<p>BMO Capital Markets' managing director of BioPharma equity research, Evan Seigerman, joins Market Catalysts with <a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/author/julie-hyman/\">Julie Hyman</a> to discuss the difference in stock reactions from the pharma giants.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-catalysts/\">Market Catalysts</a>.</p>",
        "summary": "Eli Lilly (LLY) stock is trading at record highs after the pharmaceutical company reached a deal with the White House to offer weight-loss drugs at a discount. Novo Nordisk (NVO), which was also part of Trump's GLP-1 deal, has not seen its stock climb to fresh record highs on the agreement. BMO Capital Markets' managing director of BioPharma equity research, Evan Seigerman, joins Market Catalysts with Julie Hyman to discuss the difference in stock reactions from the pharma giants. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
        "pubDate": "2025-11-11T16:31:52Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/82aecee0-bf18-11f0-b2dd-4d20884637ac",
          "originalWidth": 2092,
          "originalHeight": 1176,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uOduGncWFTLD2y8Q4zTW_w--~B/aD0xMTc2O3c9MjA5MjthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/82aecee0-bf18-11f0-b2dd-4d20884637ac.cf.webp",
              "width": 2092,
              "height": 1176,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BZq70V_1EVMwR2yFbpmGzg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/82aecee0-bf18-11f0-b2dd-4d20884637ac.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/eli-lilly-stock-soars-highs-163152645.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/eli-lilly-stock-soars-highs-163152645.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T15:50:08+00:00",
    "headline": "Three Healthcare Buys That Wall Street Loves",
    "summary": "These three healthcare stocks are outperforming most of the sector.",
    "url": "https://www.fool.com/investing/2025/11/11/three-healthcare-buys-that-wall-street-loves/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "84c624ae-6c7b-3778-b2e6-c582782cc2fb",
      "content": {
        "id": "84c624ae-6c7b-3778-b2e6-c582782cc2fb",
        "contentType": "STORY",
        "title": "Three Healthcare Buys That Wall Street Loves",
        "description": "",
        "summary": "These three healthcare stocks are outperforming most of the sector.",
        "pubDate": "2025-11-11T15:50:08Z",
        "displayTime": "2025-11-11T15:50:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/4eb997d94640733dc1e9744fa7375e63",
          "originalWidth": 1400,
          "originalHeight": 787,
          "caption": "Lab technician doing research.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jXJlkmUTEH30cgIS9SYDqg--~B/aD03ODc7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/4eb997d94640733dc1e9744fa7375e63.cf.webp",
              "width": 1400,
              "height": 787,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kaWkkUlG99zumzPk6tEiOQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4eb997d94640733dc1e9744fa7375e63.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/11/three-healthcare-buys-that-wall-street-loves/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/three-healthcare-buys-wall-street-155008925.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T15:08:00+00:00",
    "headline": "Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?",
    "summary": "Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.",
    "url": "https://finance.yahoo.com/news/lilly-18-month-buy-sell-150800926.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "419c393b-37a8-3c5a-8005-5acb4281084a",
      "content": {
        "id": "419c393b-37a8-3c5a-8005-5acb4281084a",
        "contentType": "STORY",
        "title": "Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?",
        "description": "",
        "summary": "Eli Lilly stock jumps 18% in a month as strong Q3 results, upgraded guidance and rising demand for Mounjaro and Zepbound fuel investor optimism.",
        "pubDate": "2025-11-11T15:08:00Z",
        "displayTime": "2025-11-11T15:08:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-18-month-buy-sell-150800926.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-18-month-buy-sell-150800926.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T17:11:34+00:00",
    "headline": "European Equities Rise Sharply Again in Tuesday Trading; Novo Nordisk Slashes Wegovy Prices in India to Compete With Eli Lilly",
    "summary": "The European stock markets closed sharply higher for the second straight session in Tuesday trading",
    "url": "https://finance.yahoo.com/news/european-equities-rise-sharply-again-171134179.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "065c6f00-8b3d-3e0f-bc93-487edd1d0cd8",
      "content": {
        "id": "065c6f00-8b3d-3e0f-bc93-487edd1d0cd8",
        "contentType": "STORY",
        "title": "European Equities Rise Sharply Again in Tuesday Trading; Novo Nordisk Slashes Wegovy Prices in India to Compete With Eli Lilly",
        "description": "",
        "summary": "The European stock markets closed sharply higher for the second straight session in Tuesday trading",
        "pubDate": "2025-11-11T17:11:34Z",
        "displayTime": "2025-11-11T17:11:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/european-equities-rise-sharply-again-171134179.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/european-equities-rise-sharply-again-171134179.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T19:34:53+00:00",
    "headline": "Jim Cramer on Eli Lilly: “We’re Not a Seller”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer offered insights on. Cramer discussed the future possibilities of the company’s weight loss drug, as he said: “… Eli Lilly, which I think has beaten back Danish Novo Nordisk, maybe even into submission. After all, Lilly’s on the market with a very effective […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-eli-lilly-not-193453592.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "e07c816c-a0f3-3ed3-b617-a29c64830dd7",
      "content": {
        "id": "e07c816c-a0f3-3ed3-b617-a29c64830dd7",
        "contentType": "STORY",
        "title": "Jim Cramer on Eli Lilly: “We’re Not a Seller”",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer offered insights on. Cramer discussed the future possibilities of the company’s weight loss drug, as he said: “… Eli Lilly, which I think has beaten back Danish Novo Nordisk, maybe even into submission. After all, Lilly’s on the market with a very effective […]",
        "pubDate": "2025-11-11T19:34:53Z",
        "displayTime": "2025-11-11T19:34:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5",
          "originalWidth": 700,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wyy4UWrSKL87q_fyeH45LA--~B/aD01MDA7dz03MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5.cf.webp",
              "width": 700,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AnFYVFBsFAzROcOJguXtPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-eli-lilly-not-193453592.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-eli-lilly-not-193453592.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T19:34:52+00:00",
    "headline": "Jim Cramer Says “I Think Pfizer’s Very Smart to Buy Metsera”",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer offered insights on. Cramer discussed the company’s acquisition of Metsera during the episode. He commented: “There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be bigger than others. This morning, the […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-says-think-pfizer-193452452.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ba8d2091-cc5f-3ecf-af11-324baf60c8c7",
      "content": {
        "id": "ba8d2091-cc5f-3ecf-af11-324baf60c8c7",
        "contentType": "STORY",
        "title": "Jim Cramer Says “I Think Pfizer’s Very Smart to Buy Metsera”",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer offered insights on. Cramer discussed the company’s acquisition of Metsera during the episode. He commented: “There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be bigger than others. This morning, the […]",
        "pubDate": "2025-11-11T19:34:52Z",
        "displayTime": "2025-11-11T19:34:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c",
          "originalWidth": 1920,
          "originalHeight": 1272,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lBNvOkwEcDTC6JSi8u6u5Q--~B/aD0xMjcyO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c.cf.webp",
              "width": 1920,
              "height": 1272,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l4R272WQ4gg_U7DbC5QzrA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-says-think-pfizer-193452452.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-says-think-pfizer-193452452.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]